^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
OMTX705
i
Other names: OMTX705
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
InxMed, Oncomatryx
Drug class:
Microtubule inhibitor, FAPα-targeted antibody-drug conjugate
Related drugs:
9d
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=150, Recruiting, Oncomatryx Biopharma S.L. | Trial completion date: Oct 2024 --> Dec 2027 | Trial primary completion date: Oct 2024 --> Dec 2027
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • OMTX705
over5years
OMTX705, a Novel FAP-Targeting ADC demonstrates Activity in Chemotherapy and PD1-Resistant Solid Tumors Models. (PubMed, Clin Cancer Res)
These data suggest that FAP-targeting with OMTX705 represents a novel and potent strategy for cancer treatment including tumors resistant to immunotherapy and support its clinical development.
Journal
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • PRF1 (Perforin 1)
|
OMTX705
Share via
